Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:43 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
NCT01904253 · Taiho Oncology, Inc. · PHASE2 · terminated · last registry update 2024-09-05 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The preliminary data does not suggest any safety signal, but an ad hoc interim analysis showed an imbalance of PFS between the two arms” | – | Registry record, Taiho Oncology, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TOP2A in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-06-05Phase 3 first posted: Amgen, Tarlatamab + Durvalumab (NCT07005128)
- 2025-01-30Phase 3 first posted: Gilead Sciences, Sacituzumab Govitecan (SG) + Topotecan (NCT06801834)
- 2024-12-02Phase 3 first posted: BioNTech SE, Pumitamig + Atezolizumab (NCT06712355)
- 2024-10-17Phase 3 first posted: Bristol-Myers Squibb, BMS-986489 (Atigotatug+Nivolumab) + Atezolizumab (NCT06646276)
- 2024-08-21Phase 3 first posted: AstraZeneca, Datopotamab Deruxtecan + Rilvegostomig (NCT06564844)
- 2024-01-18Phase 3 first posted: Amgen, Tarlatamab + Durvalumab (NCT06211036)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision